HDL and persistent inflammation immunosuppression and catabolism syndrome.
HDL and persistent inflammation immunosuppression and catabolism syndrome.
复制标题
DOI：
10.1097/mol.0000000000000782
复制
发表时间：
2021-10-01
影响因子：
4.4
通讯作者：
Reddy S
中科院分区：
文献类型：
--
作者：
Barker G;Winer JR;Guirgis FW;Reddy S
本文综述了高密度脂蛋白胆固醇在慢性炎症和免疫抑制引起持续性炎症、免疫抑制和分解代谢综合征（PICS）的机制背景下的免疫调节机制，并描述了潜在的治疗方法和目前研究的空白。低高密度脂蛋白（HDL）胆固醇可预测急性脓毒症的严重程度和预后。最近的研究表明，载脂蛋白是长期预后的预后指标。在过去的几年里，PICS的病理生物学机制已经被阐明。最近对相关慢性炎症疾病中HDL通路相互作用的研究可能为进一步的机制和治疗靶点提供见解。HDL显著影响与慢性疾病和炎症相关的先天和适应性免疫途径。需要进一步的研究来更好地表征PICS环境下的这些相互作用。
This paper reviews the mechanisms of high density lipoprotein cholesterol immunomodulation in the context of the mechanisms of chronic inflammation and immunosuppression causing persistent inflammation, immunosuppression, and catabolism syndrome (PICS) and describes potential therapies and gaps in current research. Low high density lipoprotein (HDL) cholesterol is predictive of acute sepsis severity and outcome. Recent research has indicated apolipoprotein is a prognostic indicator of long term outcomes. The pathobiologic mechanisms of PICS have been elucidated in the past several years. Recent research of the interaction of HDL pathways in related chronic inflammatory diseases may provide insights into further mechanisms and therapeutic targets. HDL significantly influences innate and adaptive immune pathways relating to chronic disease and inflammation. Further research is needed to better characterize these interactions in the setting of PICS.